MedPath

Veliparib

Generic Name
Veliparib
Drug Type
Small Molecule
Chemical Formula
C13H16N4O
CAS Number
912444-00-9
Unique Ingredient Identifier
01O4K0631N
Indication

与化疗药物紫杉醇和卡铂联合用于治疗乳腺癌。

Clinical Trials
Related News

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

Phase 2
Completed
Conditions
Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IV Breast Cancer AJCC v8
Locally Advanced Breast Carcinoma
Metastatic Breast Carcinoma
Unresectable Breast Carcinoma
Interventions
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
First Posted Date
2010-06-23
Last Posted Date
2024-11-22
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
74
Registration Number
NCT01149083
Locations
🇺🇸

USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

🇺🇸

University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

🇺🇸

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

and more 20 locations

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

Phase 1
Completed
Conditions
Male Breast Carcinoma
Estrogen Receptor Negative
Stage IV Breast Cancer AJCC v6 and v7
HER2/Neu Negative
Recurrent Fallopian Tube Carcinoma
Triple-Negative Breast Carcinoma
Progesterone Receptor Negative
Recurrent Breast Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma
Interventions
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
First Posted Date
2010-06-16
Last Posted Date
2017-12-22
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
45
Registration Number
NCT01145430
Locations
🇺🇸

Montefiore Medical Center-Einstein Campus, Bronx, New York, United States

🇺🇸

Montefiore Medical Center - Moses Campus, Bronx, New York, United States

🇺🇸

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States

and more 3 locations

Veliparib and Temozolomide in Treating Patients With Acute Leukemia

Phase 1
Active, not recruiting
Conditions
Acute Lymphoblastic Leukemia
Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Secondary Acute Myeloid Leukemia
Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1
Adult B Acute Lymphoblastic Leukemia
Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Alkylating Agent-Related Acute Myeloid Leukemia
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
Interventions
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
First Posted Date
2010-06-09
Last Posted Date
2025-03-11
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
66
Registration Number
NCT01139970
Locations
🇺🇸

University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

🇺🇸

University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States

🇺🇸

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor

Phase 1
Completed
Conditions
Gastric Cancer
Interventions
First Posted Date
2010-05-14
Last Posted Date
2021-08-02
Lead Sponsor
AbbVie (prior sponsor, Abbott)
Target Recruit Count
60
Registration Number
NCT01123876
Locations
🇺🇸

Site Reference ID/Investigator# 24986, Washington, District of Columbia, United States

🇺🇸

Site Reference ID/Investigator# 24987, Scottsdale, Arizona, United States

🇺🇸

Site Reference ID/Investigator# 24985, Los Angeles, California, United States

and more 5 locations

A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer

Phase 2
Completed
Conditions
Ovarian Cancer
Interventions
First Posted Date
2010-04-30
Last Posted Date
2018-06-06
Lead Sponsor
AbbVie (prior sponsor, Abbott)
Target Recruit Count
168
Registration Number
NCT01113957
Locations
🇦🇺

Site Reference ID/Investigator# 25133, Nedlands, Australia

🇺🇸

Site Reference ID/Investigator# 25029, Hilliard, Ohio, United States

🇺🇸

Site Reference ID/Investigator# 25039, Peoria, Illinois, United States

and more 29 locations

Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer

Phase 1
Completed
Conditions
Hereditary Breast/Ovarian Cancer - BRCA2
Estrogen Receptor-negative Breast Cancer
Hereditary Breast/Ovarian Cancer - BRCA1
Male Breast Cancer
HER2-negative Breast Cancer
Progesterone Receptor-negative Breast Cancer
Recurrent Breast Cancer
Stage IV Breast Cancer
Triple-negative Breast Cancer
Interventions
Other: laboratory biomarker analysis
Other: pharmacological study
First Posted Date
2010-04-15
Last Posted Date
2017-08-10
Lead Sponsor
University of Washington
Target Recruit Count
50
Registration Number
NCT01104259
Locations
🇺🇸

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer

Phase 1
Completed
Conditions
Prostate Cancer
Interventions
First Posted Date
2010-03-11
Last Posted Date
2017-11-21
Lead Sponsor
AbbVie (prior sponsor, Abbott)
Target Recruit Count
35
Registration Number
NCT01085422

A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors

Phase 1
Completed
Conditions
Advanced Solid Tumors
Interventions
First Posted Date
2010-02-05
Last Posted Date
2021-08-02
Lead Sponsor
AbbVie (prior sponsor, Abbott)
Target Recruit Count
79
Registration Number
NCT01063816

A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer

Phase 2
Completed
Conditions
Colorectal Cancer
Interventions
First Posted Date
2010-01-18
Last Posted Date
2019-04-02
Lead Sponsor
Georgetown University
Target Recruit Count
75
Registration Number
NCT01051596
Locations
🇺🇸

Georgetown University Medical Center, Washington, District of Columbia, United States

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Phase 2
Recruiting
Conditions
HER2-negative Breast Cancer
Hormone Receptor Positive Tumor
Angiosarcoma
TNBC - Triple-Negative Breast Cancer
Breast Neoplasms
Breast Tumors
HER2-positive Breast Cancer
Hormone Receptor Negative Tumor
Breast Cancer
Early-stage Breast Cancer
Interventions
Drug: Standard Therapy
Drug: AMG 386 with or without Trastuzumab
Drug: AMG 479 (Ganitumab) plus Metformin
Drug: SYD985 ([vic-]trastuzumab duocarmazine)
Drug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab
Drug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab
Drug: Datopotamab deruxtecan + Durvalumab
Drug: Rilvegostomig + TDXd
Drug: AMG 386 and Trastuzumab
First Posted Date
2010-01-05
Last Posted Date
2024-10-22
Lead Sponsor
QuantumLeap Healthcare Collaborative
Target Recruit Count
5000
Registration Number
NCT01042379
Locations
🇺🇸

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

🇺🇸

University of Texas, Southwestern Medical Center, Dallas, Texas, United States

🇺🇸

University of Kansas, Westwood, Kansas, United States

and more 33 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy